Skip to main content

Market Overview

Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock

Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock

Insys Therapeutics Inc (NASDAQ: INSY), a pharmaceutical company that focuses on a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients called Subsys, reported its fourth quarter results Thursday which prompted Piper Jaffray to downgrade the stock.

The Analyst

Piper Jaffray's David Amsellem downgraded Insys Therapeutics' stock from Neutral to Underweight with a price target lowered from $5 to $4.

The Thesis

Heading into Insys' fourth quarter print, weakness from the company's key top-line driver Subsys was expected given the pressure facing its TIRF (transmucosal immediate-release fentany) market, Amsellem said a note. As expected, sales did fall short of expectations as evident by a revenue miss but the bigger takeaway is management's guidance for a relatively stable total sales in 2018 compared to 2017.

Management's commentary naturally implies stability in the TIRF market but "this has no basis in reality" given the ongoing opioid crisis and TIRF products have been "among the most controversial agents" within the opioid space, the analyst said. Management's guidance also "flies in the face of reality" and should "raise real questions" relating to the company's judgment and credibility.

The "weak roll out" of the company's Syndros doesn't inspire any confidence in management's guidance, Amsellem said. While the company may deserve some credit for advancing its pipeline the fact is the "relatively poor execution" on Syndros casts some doubt on management's ability to successfully commercialize new products.

Price Action

Shares of Insys Therapeutics were trading lower by 3 percent Friday at $7.45.

Related Links:

Insys Accepts Founder Kapoor's Resignation, Preps $150 Million To Settle Dept. Of Justice Investigation

22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

Latest Ratings for INSY

May 2019Janney CapitalDowngradesBuyNeutral
Mar 2019RBC CapitalMaintainsOutperformOutperform
Jan 2019Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for INSY
View the Latest Analyst Ratings


Related Articles (INSY)

View Comments and Join the Discussion!

Posted-In: cancer David Amsellem Opioid Opioid TreatmentAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

DALJP MorganMaintains63.0
ALKJP MorganMaintains104.0
UALJP MorganMaintains58.0
SPGIBMO CapitalMaintains428.0
INFOBMO CapitalMaintains110.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at